Alternative Medications for Rheumatic Heart Disease Secondary Prophylaxis

Preferred Oral Alternative When Intramuscular Benzathine Penicillin G Is Not Feasible

The American Heart Association recommends oral penicillin V as the first‑line alternative for patients who cannot receive intramuscular benzathine penicillin G, with a dose of 250 mg twice daily for children and 250–500 mg twice daily for adults, administered continuously for the entire prophylaxis period. 1
The same guideline specifies a simplified dosing schedule of 250 mg orally twice daily for most children and 500 mg twice daily for adolescents and adults. 2

Sulfadiazine is endorsed as the preferred secondary‑prophylaxis agent for individuals with penicillin allergy. 1
Macrolides (e.g., erythromycin) or azalides (e.g., azithromycin) are accepted as second‑line alternatives in penicillin‑allergic patients. 1
Narrow‑spectrum oral cephalosporins such as cefadroxil or cephalexin may be used only when the patient does not have an immediate (anaphylactic‑type) hypersensitivity to penicillin, recognizing that up to 10 % of penicillin‑allergic persons are also allergic to cephalosporins. 2

For patients with a history of carditis and persistent valvular disease, prophylaxis should continue for 10 years after the last acute rheumatic fever episode or until age 40, whichever is longer; lifelong therapy is advised for high‑risk individuals. 3
For patients with carditis but no persistent valvular disease, prophylaxis should last 10 years or until age 21, whichever is longer. 3
For patients without a history of carditis, prophylaxis should be maintained for 5 years or until age 21, whichever is longer. 3

The American Heart Association advises against discontinuing secondary prophylaxis after valve surgery; prophylaxis must be continued even after prosthetic valve replacement. 3
Broad‑spectrum cephalosporins (e.g., cefaclor, cefuroxime, cefixime, cefdinir, cefpodoxime) should not be used because they are more costly and promote antibiotic‑resistant flora compared with penicillin‑based regimens. 2
Patient education and adherence support (e.g., peer groups, case management, regular follow‑up) are essential components of oral penicillin V prophylaxis programs to maximize effectiveness. 2

Phenoxymethylpenicillin (penicillin V) is used as secondary prophylaxis in rheumatic heart disease to prevent recurrent group A streptococcal pharyngitis, which can trigger acute rheumatic fever episodes and progressive valvular damage. 4
Penicillin prevents recurrence of acute rheumatic fever by eradicating group A β‑hemolytic streptococcal throat infections before they can initiate the autoimmune cascade that damages heart valves. Evidence from both the 2009 Circulation review and the 2013 Nature Reviews Cardiology article supports this mechanism. 4, 5
Patients who have experienced a single episode of rheumatic fever are at extremely high risk of subsequent attacks following further GAS pharyngitis, making continuous antimicrobial prophylaxis essential for secondary prevention. 4

Observational data indicate that 60–65 % of individuals develop progressive valvular heart disease after their initial rheumatic fever episode when prophylaxis is omitted, and recurrent attacks accelerate valve damage. 5

Penicillin is the preferred agent for secondary prophylaxis because it is cost‑effective, has a narrow antimicrobial spectrum, has long‑standing proven efficacy, and no documented resistance of group A streptococcus to penicillin has ever been reported. 4

For patients with penicillin allergy, macrolides (e.g., erythromycin) or azalides (e.g., azithromycin) are recommended as second‑line alternatives. This recommendation is supported by the 2009 Circulation guideline. 4